文献速递临床试验与 GCP基础与转化研究

舒肝清热方治疗广泛性焦虑障碍的疗效与安全性:多中心前瞻性双盲双模拟随机对照试验方案

Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial.
PubMed 文献 · Trials · 2020-03-14

本研究为多中心、前瞻性、双盲、双模拟、随机对照试验方案,计划从中国四家医院招募200例广泛性焦虑障碍(GAD)患者,按1:1随机分为舒肝清热方(SGQR)组和丁螺环酮组,进行8周治疗和6次访视,以评估SGQR的疗效与安全性。

要点

  • SGQR方在中国临床实践中已被GAD患者接受多年。
  • 试验采用双盲双模拟设计,对照组使用丁螺环酮。
  • 主要结局包括HAM-A、HAMD-17、CGI-I及炎性细胞因子。

核心结论

  • 该试验旨在为SGQR方治疗GAD的疗效和安全性提供科学客观评价。

研究设计与样本

  • 多中心、前瞻性、双盲、双模拟、随机对照试验。
  • 计划从中国四家医院招募200例符合条件的GAD患者。
  • 按1:1随机分为研究组和对照组,疗程8周,共6次访视。
  • 研究组接受SGQR方和丁螺环酮安慰剂,对照组接受丁螺环酮和SGQR安慰剂。

关键数值与推荐

  • 疗效指标包括汉密尔顿焦虑量表(HAM-A)、汉密尔顿抑郁量表-17(HAMD-17)、临床总体印象改善量表(CGI-I)、GAD中医证候量表。
  • 检测促炎细胞因子:白细胞介素-1β(IL-1β)、IL-6和肿瘤坏死因子-α。
  • 采用治疗 emergent 症状量表(TESS)评估不良反应,并记录安全性和不良事件。

临床怎么用

  • 若试验证实有效,SGQR方可能为临床医生提供GAD的替代治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Generalized anxiety disorder (GAD) is a persistent and common mental disorder that entails significant impairments in role functioning and quality of life. Currently available effective interventions include psychological therapies, self-help approaches, and pharmacological treatments, which do not quite meet clinical needs, and the ideal anxiolytic is still being sought. Shu-gan-qing-re (SGQR) formula, a Chinese patent medicine, has been well received by patients with GAD in Chinese clinical practice for years. The present prospective, double-blind, double-dummy, randomized controlled trial is designed to investigate the efficacy and safety of SGQR formula for GAD. METHODS/DESIGN: A total of 200 eligible participants will be recruited from four hospitals in different parts of China. They will be randomly assigned to either the study group or the control group in a ratio of 1:1. Participants allocated to the study group will receive SGQR formula and buspirone placebo, while buspirone and SGQR placebo will be applied in the control group. Six scheduled visits will be conducted over the course of 8 weeks. Outcome measurements include Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale-17 (HAMD-17), Clinical Global Impression-Improvement Scale (CGI-I), Traditional Chinese Medicine Syndrome Scale for GAD, and pro-inflammatory cytokine tests: interleukin-1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha. Adverse reactions will be evaluated by using the Treatment Emergent Symptom Scale (TESS). Safety outcomes and adverse events will also be recorded. DISCUSSION: The study will provide scientific and objective assessments for the efficacy and safety of SGQR formula for patients with GAD, hopefully offering clinicians an alternative approach to GAD. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ID: ChiCTR-IPR-17013058. Registered on October 20, 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Chen P, Zhu H, Ning Y, et al. Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial. Trials. 2020. PMID: 32171323. doi:10.1186/s13063-020-4186-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。